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of life for men (DLQI mean score of 4.89) compared to women.
This score reﬂects quality of life impairment similar to patients
suffering from acne or solar keratosis.
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OBJECTIVES: To assess the consequences of dermatological dis-
eases on the quality of life of the patients and to perform an eval-
uation of depressive symptomatology among them. METHODS:
Every Belgian Dermatologist received a sample of 30 question-
naires including the DLQI, the SF-12 and the CES-D. During the
“National Week of Dermatology”, each participating dermatol-
ogist distributed the questionnaire to their ﬁrst 30 patients
coming to their consulting room and they made a register of all
the dermatological diseases of their patients. The CES-D scale
allows to perform epidemiological studies of depressive sympto-
matology in the general population. A score >17 indicates a pos-
sible depressive symptomatology, a score >23 indicates a
probable depressive symptomatology. RESULTS: In total, 105
out of the 650 Belgian dermatologists completed the register. A
total of 896 questionnaires were by 513 Flemish responders
(57%) and 383 Walloon responders (43%). The male/female
ratio was 37%/63% and the mean age was 46.76 years. The
disease allocation was: Psoriasis 15%, Atopic Dermatitis &
Contact Eczema 11%, Acne 11%, Warts 9%, Dry skin 8%,
Others 46%. Possible depressive symptomatology was observed
in 36% of the population (Flemish patients: 32%; Walloons
patients: 44%). Concerning probable depressive symptomatol-
ogy, 20% of our population (Flemish patients: 17%; Walloons
atients: 26%, p < 0.01). CONCLUSIONS: Although females
generally reported greater risk of high depressive symptoms, this
is still a concern for males. In the Rield study assessing depres-
sive symptoms in older men and women (age 65 to 75), 23.1%
of women and 12.8% of men reported high depressive symp-
toms (CES-D score > or = 16). When we compare those results
with the ones obtained in our current study, it conﬁrms that der-
matological diseases result in psychological changes that seri-
ously affect patients’ lives.
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OBJECTIVES: There is a wide range of treatments for moder-
ate-to-severe psoriasis, including oral systemics, biologics, and
phototherapies; we evaluated their cost-effectiveness (in US
dollars). METHODS: We conducted a systematic review of pub-
lished, clinical studies from 1978 to 2004 describing outcomes
for moderate-to-severe psoriasis in terms of the Psoriasis Area
and Severity Index (PASI). We determined the weighted mean
PASI improvement across studies for acitretin, alefacept,
cyclosporine, efalizumab, etanercept, inﬂiximab, methotrexate,
narrowband ultraviolet B (NBUVB), broadband ultraviolet B
(BBUVB), psoralen with ultraviolet A (PUVA), BBUVB combined
with acitretin, and PUVA combined with acitretin. The model
perspective is of the US health systems payer, and includes 1-year
medication (US Average Wholesale Price) and related treatment
(Medicare reimbursement) costs. Cost-effectiveness (deﬁned as
the cost per 1% PASI improvement) was calculated as: Total
Treatment Costs [medications or phototherapy + administration
of treatment (e.g., IV infusion) + monitoring (e.g., diagnostic
procedures) + risk-adjusted costs of adverse events] divided by
mean PASI improvement. RESULTS: We found wide variation
in annual drug costs, ranging from $1388 (methotrexate) to
$24,894 (inﬂiximab). Annual costs of treatment administration
ranged from $0 (oral systemics) to $1438 (inﬂiximab). Annual
costs of monitoring ranged from $0 (etanercept) to $2,306 (ale-
facept). Risk-adjusted costs of adverse events ranged from $0 to
$98. PASI improvement varied from 37% (alefacept 15mg IV)
to 85% (PUVA with acitretin). The annual cost per 1% PASI
improvement was: $37 for methotrexate, $46 PUVA, $91
cyclosporine, $120 NBUVB, $166 PUVA with acitretin, $167
BBUVB with acitretin, $197 acitretin, $265 BBUVB, $325 inﬂix-
imab, $357 efalizumab, $390 etanercept, and $472 alefacept IM.
CONCLUSIONS: Costs of medication and efﬁcacy rates are the
primary drivers of the cost-effectiveness of treatments for mod-
erate-to-severe psoriasis. New biologic treatments do not appear
as cost-effective as oral systemic agents, phototherapy, or com-
bined phototherapy with oral systemics.
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OBJECTIVES: To compare the expected U.S. payer costs asso-
ciated with screening and early treatment of glaucoma patients
vs. non-screening of this asymptomatic progressive disease.
METHODS: A 14-year economic model was developed to eval-
uate costs associated with biennial screening and early treatment
and compare it to not-screening, resulting in patients presenting
at slightly more advanced mild stages of this progressive disease.
Total costs included screening costs, drug costs, ofﬁce visits, and
surgical treatments associated with glaucoma. Treatment costs
and disease progression rates were taken from recently published
literature. Non-screened patients were assigned zero costs for
seven years followed by treatment costs for mild disease for seven
years. Screened patients were assigned every-other-year screen-
ing cost for 14 years, with a proportion of screened patients at
risk assigned early/mild glaucoma treatment costs. Patient epi-
demiology rates were based on non-Medicare patients aged
40–64 years old. Multi-factor sensitivity analyses were con-
ducted. RESULTS: Total expected costs to “screen and treat”
over 14 years are estimated to be $8,910 per patient or $636 per
patient per year compared to “not-screen” for 7 years followed
by 7 years of treatment costs of $10,458 or $1,494 per patient
per treated year. In sensitivity analyses, the difference in total
expected plan costs varies around cost-neutral. CONCLU-
SIONS: Total expected payer costs for screening for glaucoma
will be cost neutral over the early years of the disease and will
be cost saving during the more expensive progressive years. Cost
considerations must be balanced with patient concerns of
advancing to blindness and patient/plan beneﬁt with this new
HEDIS measure.
